AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.
Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results
Clinical Trials, Low Blood Pressure, Multiple system atrophy (MSA), Neurogenic orthostatic hypotension (nOH), Parkinson's Disease, Parkinson’s disease, R&D, Rare Disorders, Serotonin And Norepinephrine Reuptake Inhibitors, TherapeuticsTheravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).
Teva Pharmaceutical Industries Ltd. inked a deal to license and develop two of MODAG GmbH’s compounds in neurodegenerative disease.
Biohaven Pharmaceutical Holding Co. Ltd. said on Sept. 27 the company’s drug candidate, verdiperstat, failed to show effectiveness in treating a rare neurological disorder called multiple system atrophy (MSA).